ATE465151T1 - 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren - Google Patents
4-aryloxy-chinolin-derivate als 5-ht6-modulatorenInfo
- Publication number
- ATE465151T1 ATE465151T1 AT06819047T AT06819047T ATE465151T1 AT E465151 T1 ATE465151 T1 AT E465151T1 AT 06819047 T AT06819047 T AT 06819047T AT 06819047 T AT06819047 T AT 06819047T AT E465151 T1 ATE465151 T1 AT E465151T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- modulators
- aryloxy
- quinoline derivatives
- formula
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70276405P | 2005-07-27 | 2005-07-27 | |
| PCT/EP2006/064304 WO2007025798A2 (en) | 2005-07-27 | 2006-07-17 | 4-aryloxy quinoline derivatives as 5-ht6 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465151T1 true ATE465151T1 (de) | 2010-05-15 |
Family
ID=37809226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06819047T ATE465151T1 (de) | 2005-07-27 | 2006-07-17 | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7307089B2 (de) |
| EP (1) | EP1910296B1 (de) |
| JP (1) | JP2009502853A (de) |
| KR (1) | KR20080030058A (de) |
| CN (1) | CN101228130A (de) |
| AT (1) | ATE465151T1 (de) |
| AU (1) | AU2006286654A1 (de) |
| BR (1) | BRPI0614483A2 (de) |
| CA (1) | CA2616473A1 (de) |
| DE (1) | DE602006013828D1 (de) |
| ES (1) | ES2341489T3 (de) |
| IL (1) | IL188927A0 (de) |
| MX (1) | MX2008001033A (de) |
| WO (1) | WO2007025798A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| ATE524456T1 (de) * | 2007-03-23 | 2011-09-15 | Abbott Gmbh & Co Kg | Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung |
| DE602007012683D1 (de) | 2007-07-19 | 2011-04-07 | Esteve Labor Dr | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente |
| ES2574154T3 (es) * | 2007-08-07 | 2016-06-15 | Abbvie Deutschland Gmbh & Co Kg | Compuestos de quinolina adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-HT6 |
| US10572665B2 (en) * | 2012-12-28 | 2020-02-25 | Fireeye, Inc. | System and method to create a number of breakpoints in a virtual machine via virtual machine trapping events |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0349062A1 (de) | 1988-06-27 | 1990-01-03 | Merck Frosst Canada Inc. | Chinolinetheralkansäuren |
| JPH04503672A (ja) | 1989-02-27 | 1992-07-02 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | 放射線増感剤としての新規なナフタレンスルホンアミド |
| MX22406A (es) | 1989-09-15 | 1994-01-31 | Pfizer | Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat). |
| DK0498722T3 (da) | 1991-02-07 | 1998-03-09 | Roussel Uclaf | Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| GB9125515D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9125485D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| JPH08311032A (ja) | 1995-05-18 | 1996-11-26 | Eisai Co Ltd | α，β−不飽和ケトン誘導体 |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| ID19609A (id) * | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| TW521072B (en) | 1997-06-02 | 2003-02-21 | Meiji Seika Kaisha | 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| ES2211175T3 (es) | 1998-09-29 | 2004-07-01 | Wyeth Holdings Corporation | Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas. |
| GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
| CA2433950A1 (en) | 2001-01-16 | 2002-07-18 | Timothy Davenport | Therapeutic chromone compounds |
| CN100509794C (zh) | 2001-01-16 | 2009-07-08 | 阿斯特拉曾尼卡有限公司 | 治疗性杂环化合物 |
| TW589312B (en) | 2001-05-25 | 2004-06-01 | Wyeth Corp | Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression |
| ATE346068T1 (de) * | 2002-03-27 | 2006-12-15 | Glaxo Group Ltd | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden |
| MY138836A (en) | 2002-03-27 | 2009-07-31 | Glaxo Group Ltd | Quinoline derivatives and their use as 5-ht6 receptor ligands |
| GB0322510D0 (en) * | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-07-17 DE DE602006013828T patent/DE602006013828D1/de active Active
- 2006-07-17 MX MX2008001033A patent/MX2008001033A/es active IP Right Grant
- 2006-07-17 KR KR1020087002062A patent/KR20080030058A/ko not_active Abandoned
- 2006-07-17 CN CNA2006800271717A patent/CN101228130A/zh active Pending
- 2006-07-17 CA CA002616473A patent/CA2616473A1/en not_active Abandoned
- 2006-07-17 AT AT06819047T patent/ATE465151T1/de active
- 2006-07-17 EP EP06819047A patent/EP1910296B1/de not_active Not-in-force
- 2006-07-17 JP JP2008523309A patent/JP2009502853A/ja active Pending
- 2006-07-17 WO PCT/EP2006/064304 patent/WO2007025798A2/en not_active Ceased
- 2006-07-17 AU AU2006286654A patent/AU2006286654A1/en not_active Abandoned
- 2006-07-17 BR BRPI0614483-7A patent/BRPI0614483A2/pt not_active IP Right Cessation
- 2006-07-17 ES ES06819047T patent/ES2341489T3/es active Active
- 2006-07-25 US US11/493,461 patent/US7307089B2/en not_active Expired - Fee Related
-
2008
- 2008-01-21 IL IL188927A patent/IL188927A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1910296B1 (de) | 2010-04-21 |
| WO2007025798A2 (en) | 2007-03-08 |
| KR20080030058A (ko) | 2008-04-03 |
| EP1910296A2 (de) | 2008-04-16 |
| WO2007025798A3 (en) | 2007-07-26 |
| US20070027161A1 (en) | 2007-02-01 |
| ES2341489T3 (es) | 2010-06-21 |
| MX2008001033A (es) | 2008-03-19 |
| US7307089B2 (en) | 2007-12-11 |
| AU2006286654A1 (en) | 2007-03-08 |
| BRPI0614483A2 (pt) | 2011-03-29 |
| JP2009502853A (ja) | 2009-01-29 |
| DE602006013828D1 (en) | 2010-06-02 |
| CA2616473A1 (en) | 2007-03-08 |
| CN101228130A (zh) | 2008-07-23 |
| IL188927A0 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
| MX2010003155A (es) | Derivados de ciclopropil aril amida y uso de los mismos. | |
| DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| MX2010003156A (es) | Derivados de aril amida substituida con tetrazol y usos de los mismos. | |
| SE0401971D0 (sv) | Piperidne derivatives | |
| EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение | |
| NO20080110L (no) | Benzimidazolderivativer som 5-HT6,5-HT24 | |
| ATE409179T1 (de) | Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| MA32834B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
| ATE396183T1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
| IL188927A0 (en) | Aryloxy quinolines and uses thereof as 5-ht6 modulators | |
| TW200637817A (en) | 5-aminoindole derivatives | |
| EP1845780A4 (de) | Verwendung von methylphenidat-derivaten | |
| SE0403118D0 (sv) | New compounds 2 | |
| MX2009001572A (es) | Derivados de arilpiperazina y usos de los mismos. | |
| ATE374751T1 (de) | 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1910296 Country of ref document: EP |